Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

RCT (n=8238) found that among patients with type 2 diabetes and atherosclerotic CVD, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events (occurred in 11.9% in each group; 0.97; 95.6% CI, 0.85 to 1.11; p<0.001 for non-inferiority).

Source:

New England Journal of Medicine